We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Cartilage Destruction Blocked by Amazon Rainforest Product

By HospiMedica staff writers
Posted on 07 Nov 2007
A natural product derived from the Amazon rainforest is a remarkably potent antioxidant, preventing the destruction of human cartilage. More...


Researchers from the Case Western Reserve University (Cleveland, OH, USA) school of medicine and Albany Medical College (NY, USA) discovered that the product, called Progrado--an extract from a rainforest tree called Sangre de Grado (Croton palanostigma) prevented the destruction of human cartilage by blocking the action of molecular scissors called matrix metalloproteinases (MMPs) and promoting the production of the cartilage repair factor, IGF-1. According to the researchers, MMPs cut collagen, which forms the backbone of the cartilage, into tiny pieces during states of inflammation and alter the fabric that holds tissues together. The discovery's unique action suggests a broad set of applications in various joint, skin and gastrointestinal diseases, including osteoarthritis, irritable bowel syndrome, and wrinkles, based on their involvement in tissue injury/repair and aging. The study was published in the August 14, 2007, edition of the Journal of Inflammation.

"This is an exciting finding,” said senior author Tariq Haqqi, M.D., a professor of medicine at Case Western Reserve. "This is the first time a natural product has been shown to directly block these molecular scissors while showing potential to stimulate repair. This is a testament to the wound healing properties of this traditional medicine and the distinctive therapeutic opportunities that nature offers.”

Progrado was developed by Rainforest Nutritionals (Raleigh, NC, USA), which develops innovative therapeutics from natural products. Reparagen, another natural product for joint health, was developed by the company with a grant from the U.S. National Institutes of Health (NIH, Bethesda, MD, USA).


Related Links:
Case Western Reserve University
Albany Medical College
Rainforest Nutritionals

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Floor‑Mounted Digital X‑Ray System
MasteRad MX30+
IV Therapy Cart
Avalo I.V Therapy Cart
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The researchers grew pancreatic tissue (above) so it incorporated a mesh-like electronic network (red). Cells within the tissue produce insulin (green). (Photo courtesy of Penn Medicine)

‘Cyborg’ Transplants Could Replace Pancreatic Tissue Damaged by Diabetes

Type 1 diabetes destroys insulin-producing islet cells, forcing patients to rely on lifelong insulin therapy or scarce organ transplants. Although lab-grown pancreatic tissue offers a promising alternative,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.